Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics
暂无分享,去创建一个
A. Meola | S. Kernéis | R. Longley | M. White | I. Mueller | M. Backovic | S. Fafi-Kremer | C. Demeret | J. de Seze | N. Nekkab | B. Terrier | S. Petres | S. Merkling | J. Seze | J. Rosado | C. Cockram | S. Pelleau | F. Déjardin | B. Terrier | Ivo Mueller | Rhea J. Longley
[1] M. Harbers,et al. IgG Antibody Responses Are Preferential Compared With IgM for Use as Serological Markers for Detecting Recent Exposure to Plasmodium vivax Infection , 2020, medRxiv.
[2] Nicolas Carlier,et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.
[3] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[4] B. Greenhouse,et al. Are SARS-CoV-2 seroprevalence estimates biased? , 2020, The Journal of infectious diseases.
[5] A. Gelman,et al. Bayesian Analysis of Tests with Unknown Specificity and Sensitivity , 2020, medRxiv.
[6] A. Fontanet,et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France , 2020, EBioMedicine.
[7] A. Azman,et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward , 2020, Science Immunology.
[8] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[9] O. Tsang,et al. Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients , 2020, medRxiv.
[10] M. Harbers,et al. Development and validation of serological markers for detecting recent Plasmodium vivax infection , 2020, Nature Medicine.
[11] Y. Yazdanpanah,et al. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors. , 2020, medRxiv.
[12] F. Rieux-Laucat,et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients , 2020, medRxiv.
[13] N. Watkins,et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays , 2020, medRxiv.
[14] D. Larremore,et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys , 2020, medRxiv.
[15] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease , 2020, medRxiv.
[16] Juan A. Siordia,et al. Epidemiology and clinical features of COVID-19: A review of current literature , 2020, Journal of Clinical Virology.
[17] K. Krogfelt,et al. Evaluation of nine commercial SARS-CoV-2 immunoassays , 2020, medRxiv.
[18] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[19] Xavier Duval,et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series , 2020, The Lancet Infectious Diseases.
[20] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[21] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Y. Yazdanpanah,et al. SARS-CoV-2 specific antibody responses in COVID-19 patients , 2020, medRxiv.
[23] Pu Liao,et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice , 2020, medRxiv.
[24] A. Diallo,et al. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials. , 2019, The Lancet. Infectious diseases.
[25] J. Lessler,et al. Estimating cholera incidence with cross-sectional serology , 2019, Science Translational Medicine.
[26] C. Sundling,et al. Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure , 2019, BMC Medicine.
[27] Barney S. Graham,et al. Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis , 2018, Scientific Reports.
[28] M. Harbers,et al. Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection , 2018, bioRxiv.
[29] Daniel Wrapp,et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis , 2018, Scientific Reports.
[30] Kyoung-Ho Song,et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.
[31] C. Sokhna,et al. Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities , 2017, PloS one.
[32] J. Rayner,et al. Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand , 2017, Malaria Journal.
[33] D. Mabey,et al. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies , 2017, PLoS neglected tropical diseases.
[34] M. Kretzschmar,et al. Linking the seroresponse to infection to within-host heterogeneity in antibody production. , 2016, Epidemics.
[35] Kwaku Poku Asante,et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial , 2015 .
[36] Peter D. Crompton,et al. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities , 2015, Proceedings of the National Academy of Sciences.
[37] D. Conway,et al. Dynamics of the antibody response to Plasmodium falciparum infection in African children. , 2014, The Journal of infectious diseases.
[38] Kwaku Poku Asante,et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine , 2014, BMC Medicine.
[39] Niel Hens,et al. Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus , 2012, PLoS Comput. Biol..
[40] Peter J. Diggle,et al. Estimating Prevalence Using an Imperfect Test , 2011 .
[41] Peter B Gilbert,et al. A framework for assessing immunological correlates of protection in vaccine trials. , 2007, The Journal of infectious diseases.
[42] Lin‐Fa Wang,et al. Duration of Antibody Responses after Severe Acute Respiratory Syndrome , 2007, Emerging infectious diseases.
[43] W. Cao,et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. , 2007, The New England journal of medicine.
[44] Wei Liu,et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.
[45] M. Chan-yeung,et al. Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance , 2006, Respirology.
[46] D. Tyrrell,et al. The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.
[47] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.